Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Biomarkers

Topic: Genetics and APOE

Plain-language summary

Objectives To determine whether the rare APOE3 Christchurch (APOE3 Ch ) variant, known to delay clinical onset in PSEN1 E280A -associated autosomal-dominant Alzheimer's disease (ADAD), also attenuates age-related changes in plasma biomarkers of neurodegeneration and neuroinflammation. Methods In this cross-sectional study, plasma Aβ42/40, phosphorylated tau 181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) were quantified in 134 members of the Colombian PSEN1 E280A kindred, including eight heterozygous APOE3 Ch -PSEN1 E280A carriers and 14 APOE3 Ch -only carriers. Results APOE3 Ch heterozygosity was associated with significantly attenuated age-related increases in GFAP (f²=0.247), p-tau181 (f²=0.133), and NfL (f²=0.133) among PSEN1 E280A carriers. No significant effect was observed for Aβ42/40, nor among non-carriers. Elevated GFAP and NfL concentrations correlated with poorer memory performance in mutation carriers. Discussion APOE3 Ch -associated resilience is measurably reflected in plasma biomarker trajectories, indicating attenuation of both neuroinflammatory and neurodegenerative processes. Plasma GFAP, p-tau181, and NfL emerge as candidate pharmacodynamic markers for clinical trials targeting APOE3 Ch -mediated mechanisms. These findings open a new avenue for monitoring resilience-based therapeutic strategies in ADAD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Malotaux, V., Tristão-Pereira, C., Zuluaga, Y., Munoz, C., Guerrero, A., Bocanegra, Y., et al. (2026). Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers. Research Square. https://doi.org/10.21203/rs.3.rs-10705602/v1

Vancouver

Malotaux V, Tristão-Pereira C, Zuluaga Y, Munoz C, Guerrero A, Bocanegra Y, et al. Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers. Research Square. 2026. doi:10.21203/rs.3.rs-10705602/v1.

BibTeX

@article{malotaux2026-6c38e2c0,
  author  = {Malotaux, V. and Tristão-Pereira, C. and Zuluaga, Y. and Munoz, C. and Guerrero, A. and Bocanegra, Y. and Alzate, D. and Serna, L. and others},
  title   = {{Plasma Biomarker Profiles in a Colombian Cohort of Heterozygous APOE3-Christchurch Carriers}},
  journal = {Research Square},
  year    = {2026},
  doi     = {10.21203/rs.3.rs-10705602/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-10705602/v1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 17 of the 62 points it could be judged on, which is 27 of 100. Raw total 27 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 27 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 27 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 17 of the 62 points we could judge it on, which is 27 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (Research Square)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 17 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 17 of the 62 points we could judge it on is 27 out of 100.
Total 27 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “p-tau217”

692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →